louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05882825: The Level of Knowledge and Awareness of Dry Needling Treatment in the Turkish Population
Official title: The Level of Knowledge and Awareness of Dry Needling Treatment in the Turkish Population
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dry Needling
Lead sponsor: Uskudar State Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Başakşehir Çam & Sakura City Hospital
First posted: 2023-05-31
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who applied to the physical medicine and rehabilitation outpatient clinic and gave consent to participate in the study.

Brief summary: The study will employ a cross-sectional design to assess the level of knowledge and awareness of dry needling therapy in the Turkish population.

Detailed description: A representative sample of individuals will be selected for participation in the survey. A structured questionnaire will be developed specifically for this study, consisting of questions related to the knowledge and awareness of dry needling therapy. The questionnaire will be administered through face-to-face interviews. Data collected from the survey will be analyzed using appropriate statistical methods to determine the overall level of knowledge and awareness of dry needling therapy among the Turkish population.

Eligibility criteria: Inclusion Criteria:

* Giving consent.

Exclusion Criteria:

* Not giving consent.
* Any illness or disability that can prevent filling out the form or communicating.

Primary outcomes:
measure: Level of Knowledge and Awareness of Dry Needling Therapy in the Turkish Population
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Uskudar State Hospital
name: Mustafa H Temel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01422525: Changes of the Peripapillary Retinal Nerve Fiber Layer After Filtration Surgery in Glaucoma Patients
Official title: Effect of Trabeculectomy on Peripapillary Retinal Nerve Fiber Layer Thickness Using Spectral Domain Optical Coherence Tomography
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Nerve Fiber Bundle Defect
Optic Nerve Diseases
Lead sponsor: University Eye Hospital, Würzburg
Sponsor class: OTHER
First posted: 2011-08-24
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: glaucoma patients

Brief summary: At present, trabeculectomy is the most common performed and effective surgical method of filtration surgery for patients with medically uncontrolled glaucoma.

The aim of this prospective observational case study is to determine changes of the peripapillary retinal nerve fiber layer thickness using spectral domain optical coherence tomography in patients with glaucoma after surgical reduction of intraocular pressure.

Detailed description: Baseline and postoperative measurement of the peripapillary retinal nerve fiber layer (RNFL) thickness will be performed using the following spectral domain optical coherence tomography (OCT): Cirrus™ HD-OCT (Carl Zeiss Meditec) and Spectralis® Heidelberg-Engineering.

The main outcome measures will be changes in overall and quadrant RNFL thickness with respect to reduction in intraocular pressure (IOP), correlation between RNFL thickness and alteration in visual field and predictive factors of postoperative IOP-reduction and changes of RNFL thickness.

Eligibility criteria: Inclusion Criteria:

* primary or secondary open angle glaucoma
* target intraocular pressure under medical treatment was not reached
* progression of visual loss
* best corrected visual acuity of 20/100 or more
* spherical equivalent refraction of -8.0 to +4.0 D
* perimetry: less than 20% false positive answers

Exclusion Criteria:

* primary or secondary angle closure glaucoma
* congenital glaucoma
* normal tension glaucoma
* neovascular glaucoma

Primary outcomes:
measure: change of retinal nerve fiber layer thickness
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wuerzburg
country: Germany
facility: University Eye Hospital Wuerzburg
state: Bavaria
Study officials:
References:
Clinical trial NCT02713425: Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study
Official title: Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Keywords: Anxiety
Social Phobia
Separation Anxiety
Generalized Anxiety
GAD
Phobia
video game
teen
youth
child
adolescent
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2016-03-18
Enrollment: 20
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This research study aims to test the feasibility and effectiveness of using an entertaining video game as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those youth who may have limited access to mental health treatment in the traditional clinical setting.

Detailed description: The purpose of this research is to learn whether or not youth with social anxiety find a therapeutic video game engaging and useful. Children between the ages of 7 \& 17 who have been diagnosed with a social anxiety disorder will be invited to participate in this study.

Eligibility criteria: Inclusion Criteria:

1. Age 7 to 17
2. Primary diagnosis of:

   1. social phobia,
   2. separation anxiety disorder
3. A parent or other primary care giver available to participate with the child in all assessment and treatment activities
4. Estimated average intelligence
5. English speaking
6. Received les than 3 treatment sessions for social anxiety disorder

Exclusion Criteria:

1. History of and/or current diagnosis of:

   1. psychosis,
   2. autism,
   3. bipolar disorder,
   4. mental retardation,
   5. oppositional defiant disorder,
   6. PTSD,
   7. selective mutism, or
   8. major depressive disorder
2. Current suicidality or recent suicidal behavior
3. Parent to be involved in study who is unable to adequately participate due to intellectual or psychiatric difficulties
4. Starting or changing the dosage of a psychiatric medication in the last two months

Primary outcomes:
measure: Mean Change From Baseline in Subjective Units of Distress Scale (SUDS) at End of Session
timeFrame: approximately 10 minutes
Secondary outcomes:
measure: Average Child Rating of Preferring the Game to Not Having the Game
timeFrame: approximately 30 minutes
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Stephen Whiteside, Ph.D., L.P.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05527925: Effects of Visual Reconstruction on Brain Function and Structure in Children With Congenital Cataract
Official title: Effects of Visual Reconstruction on Brain Function and Structure in Children With Congenital Cataract
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Congenital Cataracts
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2022-09-06
Enrollment: 100
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with congenital cataracts

Brief summary: Children have considerable plasticity of the visual system during the formation and maturation of various visual functions at different ages. Congenital cataracts are the leading cause of treatable blindness in children. With the continuous improvement of surgical approaches and surgical techniques, the success rate of congenital cataract surgery has been significantly improved clinically, and the visual function of children has been significantly improved after surgery. However, to date, there has been no experimental study of specific changes in the brain before and after surgery in children with congenital cataracts to explore its relationship with visual reconstruction. We aim to investigate the effects of congenital cataract surgery on the brain function and structure of children through preoperative and postoperative analysis and comparison of brain imaging such as BOLD-fMRI and DTI, and provide new ideas for the clinical treatment and prognostic assessment of this disease.


Eligibility criteria: Inclusion Criteria:

* Children with congenital cataracts

Exclusion Criteria:

* Other oculo-cerebral and systemic diseases that may affect the outcome

Primary outcomes:
measure: Change from functional magnetic resonance imaging
timeFrame: 1 week before surgery , 1 month, 3 month, 6 month after surgery
Secondary outcomes:
measure: Change from best corrected visual acuity
timeFrame: 1 week before surgery , 1 month, 3 month, 6 month after surgery
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: SunYat-senU
state: Guangdong
Study officials:
affiliation: Study Principal Investigator
name: Haotian Lin
role: STUDY_DIRECTOR
References:
Clinical trial NCT03565822: The Impact of the Birth of a Child With a Rare Abdomino-thoracic Malformation
Official title: Qualitative Study of the Impact of the Birth of a Child With a Rare Abdomino-thoracic Malformation on the Parental Adjustment of the First Year
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congenital Malformation
Keywords: Oesophageal Atresia
Congenital Diaphragmatic Hernia
Short Bowel Syndrome
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
Collaborators: name: University of Lille Nord de France
First posted: 2018-06-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Qualitative study in psychology whose main objective is to propose a grounded theory to report the dynamics of parental adjustment for the period from the announcement of the diagnosis to one year of the child affected by a rare thoracic abdominal congenital malformation, requiring neonatal surgery.


Eligibility criteria: Inclusion Criteria:

* to be the parent of a child aged 12 to 36 months old having undergone neonatal surgery following oesophageal Atresia, congenital diaphragmatic hernia or short bowel syndrome diagnosis.
* to have lived with the child during his first year of life
* to have social security coverage
* to speak french

Exclusion Criteria:

* to be a person not having the capacity to consent or enjoying social protection (tutorship or guardianship);
* to be a person deprived of liberty;
* to be a minor;
* to be pregnant.

Primary outcomes:
measure: Level of the dynamics parental adjustment for the period from the announcement of the diagnosis to one year of the child with a rare abdominothoracic malformation requiring neonatal surgery.
timeFrame: at 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Jeanne de Flandres, CHU
Study officials:
affiliation: University Hospital, Lille
name: Laurent Michaud, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00662922: Consequences of Hypoglycemia on Intensive Care Unit (ICU) Patients
Official title: Does Hypoglycemia Under Intensive Insulin Therapy During Critical Illness Lead to Neurocognitive Dysfunction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Illness
Keywords: critical illness
hypoglycemia
neurocognitive dysfunction
intensive insulin therapy
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
First posted: 2008-04-21
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All patients who were admitted to the hospital ICU after 2003 are screened for hypoglycemia

Brief summary: Hypoglycemia occurs frequently during intensive blood glucose control in critically ill patients. The incidence of hypoglycaemia is associated with impaired outcome. However, it is hitherto unknown if hypoglycaemia itself predisposes patients to neurological impairment, e.g. cognitive dysfunction, or if it is the underlying medical condition that makes the patient prone to a high risk of hypoglycaemia and, concomitantly, neurocognitive impairment. Therefore we investigate neurocognitive function in patients who had hypoglycemias during their intensive care stay and compare the results to patients without hypoglycaemia whose medical conditions are matched to the hypoglycaemia patients.


Eligibility criteria: Inclusion Criteria:

* all patients

Exclusion Criteria:

* clinical diagnosis of diabetes mellitus
* brain injury of any kind prior to or upon ICU-admission
* pre-existing mental or psychiatric disorder
* terminal kidney or liver failure prior admission
* drug abuse,
* CPR \> 5 min
* HIV
* Lues

Primary outcomes:
measure: neurocognitive function
timeFrame: 1 year after ICU discharge
Secondary outcomes:
measure: neurocognitive function
timeFrame: 2,3, and 4 years after ICU discharge
Other outcomes:
Locations:
city: Münster
country: Germany
facility: Department of Anesthesiology and Intensive Care, University Hospital Münster
Study officials:
affiliation: Department of Anesthesiology and Intensive Care Medicine, University Hospital Muenster
name: Björn Ellger, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Duning T, van den Heuvel I, Dickmann A, Volkert T, Wempe C, Reinholz J, Lohmann H, Freise H, Ellger B. Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction. Diabetes Care. 2010 Mar;33(3):639-44. doi: 10.2337/dc09-1740. Epub 2009 Dec 23.
Clinical trial NCT00655122: Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
Official title: Double-Blind, Placebo-Controlled, Pilot Study, In Medical Patients With Prophylaxis Of Venous Thromboembolism in Primary Care
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Thromboembolism
Deep Vein Thrombosis
Dalteparin
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-04-09
Enrollment: 8
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects. The secondary objective was a pharmacoeconomic evaluation of hromboprophylaxis with dalteparin sodium in primary care medical subjects.

Detailed description: The study was prematurely terminated on December 9, 2003. The reason for the early termination was not related to a safety or efficacy issue. It was related to the difficulty in recruiting patients.

Eligibility criteria: Inclusion Criteria:

* Age \> 65 years
* Confinement to bed for more than 3 days, due to:
* Heart failure
* Exacerbated chronic obstructive pulmonary disease
* Acute rheumatic involvement
* Written informed consent

Exclusion Criteria:

1. Cancer
2. Anticoagulant treatment in the previous 3 months
3. Stroke or major surgery in the previous 3 months
4. Systolic pressure \>200 mmHg or diastolic pressure \>120 mmHg
5. Known chronic hepatopathy
6. Active hemorrhage in any site in the previous 3 months
7. Active peptic ulcer
8. Bacterial endocarditis
9. Conditions that can increase the risk of hemorrhage
10. Known coagulation disorders
11. Hypersensitivity to heparin or HIT
12. Life expectancy of less than 3 months
13. Previous confinement to bed during more than 3 days

Primary outcomes:
measure: Incidence of the endpoint made up of objectively demonstrated deep vein thrombosis (DVT), pulmonary embolism (PE) diagnosed by objective tests or death at the end of the follow-up period, 1 month after the end of the bedridden period.
timeFrame: 1 month
Secondary outcomes:
measure: Incidence of symptomatic deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE) and tolerability at the end of the follow-up period.
timeFrame: 1 month
Other outcomes:
Locations:
city: Leon
country: Spain
facility: Pfizer Investigational Site
city: Madrid
country: Spain
facility: Pfizer Investigational Site
city: Madrid
country: Spain
facility: Pfizer Investigational Site
city: Parla
country: Spain
facility: Pfizer Investigational Site
city: Torremolinos
country: Spain
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00870922: Effects of Masseter Manual Therapy on Temporomandibular Dysfunction
Official title: Effects of Masseter Manual Therapy on Temporomandibular Dysfunction: A Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Temporomandibular Joint
Temporomandibular Joint Dysfunction Syndrome
Temporomandibular Joint Disorder
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2009-03-27
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Muscles and myofascial dysfunction are more often the mechanism and source of pain in oral fascial disorders (OFD) than the TMJ. Masticatory muscles in patients with TMJ alterations are more hypertonic, less efficient and more prone to fatigue compared to age and sex matched controls. It is our opinion that Active Release Technique can be a reliable assessment and treatment tool in the resolution in cervical-cranio mandibular disorders. Our goal is to improve masticatory function through treatment of trigger points in the masseter.

Detailed description: Recruit 45 patients with TMD determined by questionnaire. Measure pre and post mandibular active range of motion and VAS pain scale. Treatment will include 4 visits over a two week span measuring before first treatment and after last treatment. There will be 3 treatment groups; active release technique, post isometric relaxation and a no treatment control group. We will analyze data for any change in mandibular range of motion and VAS pain scale.

Eligibility criteria: Inclusion Criteria:

* Difficulty and/or pain when opening mouth
* Jaw locking
* Difficulty or pain when chewing or talking
* TMJ clicking
* Jaw stiffness, tightness, or fatigue
* Pain in ear, temple or cheeks
* Frequent headaches, neckaches, toothaches
* Change in occlusion

Exclusion Criteria:

* Trauma to head, neck or jaw within last 12 months
* Recent dental extractions
* Taking prescription analgesics/muscle relaxants
* Recent cervical SMT (HVLA)
* Already under care for condition
* Sinus infection

Primary outcomes:
measure: Range of Motion
timeFrame: 2 weeks
Secondary outcomes:
measure: VAS pain scale
timeFrame: 2 Weeks
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan University, College of Chiropractic
state: Missouri
Study officials:
References:
Clinical trial NCT04309422: Texture Features and PDL1 in CT-PET 18 FDG
Official title: Correlation Between Texture Features With CT-PET 18 FDG and Overexpression of PDL1 in Non-small-cell Lung Carcinomas During the Initial Staging.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Small Cell Lung Cancer
Keywords: Correlation between overexpression of PDL1
texture features
CT-PET 18 FDG
Non Small Cell Lung Carcinoma
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-03-16
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient with initial CT-PET 18 FDG realized in the nuclear service of Montpellier university hospital, with non small cell lung carcinoma diagnosed with biopsy of the primitive site or local drainage lymphadenopathy.

Brief summary: Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in non-small cell lung carcinomas during the inital staging.

The hypothesis is that overexpression of PDL1is correlated with at least one texture feature among those selected.

84 CT-PET 18 FDG at the initial staging of a non small cell lung carcinoma (adenocarcinoma or squamous cell carcinoma), whose the biopsed site was the primitive site or the drainage lymphadenopathy, without previous treatment, were recruited and analyzed by a software allowing to estimate texture features.


Eligibility criteria: Inclusion criteria:

* adult patient ;
* first CT-PET 18 FDG realized for the inital staging ;
* absence of previous treatment for a thoracic neoplasm ;
* biopsy realized on the primitive site or local drainage lymphadenopathy ;
* primitive site viewable with morphological imagery ;
* availability of evaluation of PDL1's overexpression ;

Exclusion criteria

- Refusal to participate in this research

Primary outcomes:
measure: Correlation between at least one texture feature and overexpression of PDL1
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uh Montpellier
Study officials:
affiliation: University Hospitals of Montpellier
name: Jean-Baptiste MALLET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00932022: Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Obesity
Overactive Bladder
Incontinence
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2009-07-02
Enrollment: 127
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.


Eligibility criteria: Inclusion Criteria:

* OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence
* Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).
* Obese

Exclusion Criteria:

* Chronic kidney failure
* Abdominal bypass surgery for obesity
* Moderate or severe memory impairment
* Uncontrolled narrow angle glaucoma
* Uncontrolled systemic disease
* Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia

Primary outcomes:
measure: Percent Change From Baseline in Urinary Urgency Incontinence (UUI)
timeFrame: Baseline (Week 2), Week 14
Secondary outcomes:
measure: Percent Change From Baseline in Urgency Severity Associated With Toilet Voids
timeFrame: Baseline (Week 2), Week 14
measure: Percent Change From Baseline in Voided Volume
timeFrame: Baseline (Week 2), Week 14
measure: Percent Change From Baseline in Over Active Bladder (OAB)-Symptom Composite Score
timeFrame: Baseline (Week 2), Week 14
measure: Percent Change From Baseline in Percentage of Patients Continent
timeFrame: Baseline (Week 2), Week 14
Other outcomes:
Locations:
city: La Mesa
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References: